{"id":20248,"date":"2025-09-01T10:22:15","date_gmt":"2025-09-01T10:22:15","guid":{"rendered":"https:\/\/itbt-staging-68b209.ingress-earth.ewp.live\/?p=20248"},"modified":"2025-09-01T10:22:15","modified_gmt":"2025-09-01T10:22:15","slug":"eisais-tazemetostat-approved-as-orphan-drug-in-japan","status":"publish","type":"post","link":"https:\/\/demo.itbusinesstoday.com\/ja\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/","title":{"rendered":"\u30a8\u30fc\u30b6\u30a4\u306e\u30bf\u30bc\u30e1\u30c8\u30b9\u30bf\u30c3\u30c8\u304c\u65e5\u672c\u3067\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306b\u6307\u5b9a"},"content":{"rendered":"<p>\u30a8\u30fc\u30b6\u30a4\u682a\u5f0f\u4f1a\u793e\uff08\u672c\u793e\uff1a\u6771\u4eac\u90fd\u3001\u793e\u9577\uff1a\u5185\u85e4\u6674\u592b\uff09\u306f\u3001\u3053\u306e\u305f\u3073\u3001\u6297\u60aa\u6027\u816b\u760d\u5264EZH2\u963b\u5bb3\u5264\u300c\u30bf\u30bc\u30e1\u30c8\u30b9\u30bf\u30c3\u30c8\u81ed\u5316\u6c34\u7d20\u9178\u5869\u300d\uff08\u4e00\u822c\u540d\u3001\u88fd\u54c1\u540d\u300c\u30bf\u30ba\u30d9\u30ea\u30c3\u30af\u00ae\u9320200mg\u300d\u3001\u4ee5\u4e0b\u300c\u30bf\u30bc\u30e1\u30c8\u30b9\u30bf\u30c3\u30c8\u300d\uff09\u306b\u3064\u3044\u3066\u3001\u5316\u5b66\u7642\u6cd5\u65bd\u884c\u5f8c\u306b\u9032\u884c\u3057\u305f\u5207\u9664\u4e0d\u80fd\u306aINI1\u9670\u6027\u4e0a\u76ae\u8089\u816b\u3092\u52b9\u80fd\u30fb\u52b9\u679c\u3068\u3057\u3066\u3001\u539a\u751f\u52b4\u50cd\u7701\u3088\u308a\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u306e\u6307\u5b9a\u3092\u53d7\u3051\u305f\u3068\u767a\u8868\u3057\u307e\u3057\u305f\u3002<\/p>\n<p>\u4e0a\u76ae\u8089\u816b\u306f\u8edf\u90e8\u8089\u816b\u306e\u4e00\u7a2e\u3067\u3042\u308a\u3001\u8edf\u90e8\u8089\u816b\u5168\u4f53\u306e\u7d041%\u3092\u5360\u3081\u308b\u3068\u63a8\u5b9a\u3055\u308c\u308b\u5e0c\u5c11\u304c\u3093\u3067\u3059\u3002\u6cbb\u7642\u306e\u9078\u629e\u80a2\u306f\u9650\u3089\u308c\u3066\u304a\u308a\u3001\u30a2\u30f3\u30e1\u30c3\u30c8\u30fb\u30e1\u30c7\u30a3\u30ab\u30eb\u30fb\u30cb\u30fc\u30ba\u306f\u975e\u5e38\u306b\u9ad8\u3044\u3002<\/p>\n<p>\u30bf\u30bc\u30e1\u30c8\u30b9\u30bf\u30c3\u30c8\u306f\u3001\u518d\u767a\u53c8\u306f\u96e3\u6cbb\u6027\u306eEZH2\u907a\u4f1d\u5b50\u5909\u7570\u967d\u6027\u306e\u6ffe\u80de\u6027\u30ea\u30f3\u30d1\u816b\uff08\u6a19\u6e96\u6cbb\u7642\u304c\u9069\u7528\u3067\u304d\u306a\u3044\u5834\u5408\u306b\u9650\u308b\uff09\u3092\u9069\u5fdc\u75c7\u3068\u3057\u3066\u30012021\u5e746\u6708\u306b\u65e5\u672c\u3067\u627f\u8a8d\u3055\u308c\u307e\u3057\u305f\u3002\u5316\u5b66\u7642\u6cd5\u5f8c\u306b\u9032\u884c\u3057\u305fINI1\u9670\u6027\u306e\u5207\u9664\u4e0d\u80fd\u306a\u4e0a\u76ae\u8089\u816b\u306b\u5bfe\u3057\u3066\u306f\u3001\u30bf\u30bc\u30e1\u30c8\u30b9\u30bf\u30c3\u30c8\u306e\u7b2c\u2161\u76f8\u533b\u5e2b\u4e3b\u5c0e\u6cbb\u9a13\uff08A Phase II Trial of Tazemetostat for Patients with Unreresectable or Metastatic Epithelioid Sarcoma\uff1a\u73fe\u5728\u3001\u56fd\u7acb\u304c\u3093\u7814\u7a76\u30bb\u30f3\u30bf\u30fc\u4e2d\u592e\u75c5\u9662\u304c\u4e3b\u5c0e\u3059\u308bTAZETTA\u8a66\u9a13\uff09\u304c\u9032\u884c\u4e2d\u3067\u3059\u3002<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbt-staging-68b209.ingress-earth.ewp.live\/health-tech\/pharma\/austria-and-germany-first-in-eu-to-launch-leqembi\/\" rel=\"bookmark\">\u30aa\u30fc\u30b9\u30c8\u30ea\u30a2\u3068\u30c9\u30a4\u30c4\u304cEU\u3067\u521d\u3081\u3066LEQEMBI\u3092\u767a\u58f2<\/a><\/h4>\n<p><a href=\"https:\/\/www.eisai.com\/\">\u30a8\u30fc\u30b6\u30a4<\/a> \u306f\u3001\u304c\u3093\u9818\u57df\u3092\u91cd\u70b9\u9818\u57df\u306e\u3072\u3068\u3064\u3068\u4f4d\u7f6e\u3065\u3051\u3001\u304c\u3093\u306e\u6cbb\u7652\u3092\u76ee\u6307\u3057\u305f\u753b\u671f\u7684\u306a\u65b0\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u79c1\u305f\u3061\u306f\u3001\u4e16\u754c\u4e2d\u306e\u304c\u3093\u60a3\u8005\u3055\u3093\u3001\u305d\u306e\u3054\u5bb6\u65cf\u3001\u533b\u7642\u5f93\u4e8b\u8005\u306e\u591a\u69d8\u306a\u30cb\u30fc\u30ba\u306b\u5fdc\u3048\u3001\u60a3\u8005\u3055\u3093\u306b\u63d0\u4f9b\u3055\u308c\u308b\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u306e\u5411\u4e0a\u306b\u52aa\u3081\u3066\u3044\u304d\u307e\u3059\u3002<\/p>\n<p><strong>\u30bd\u30fc\u30b9 <a href=\"https:\/\/www.eisai.com\/news\/2025\/news202558.html\">\u30a8\u30fc\u30b6\u30a4\u00a0<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. announced that it has received orphan drug designation for anticancer agent the EZH2 inhibitor tazemetostat hydrobromide (generic name, product name \u201cTazverik\u00ae Tablets 200 mg\u201d, \u201ctazemetostat\u201d) for unresectable INI1-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). Epithelioid sarcoma is a type of soft tissue sarcoma that is a rare cancer estimated to account for about 1% of all soft tissue sarcoma.1 Only 174 cases were registered from major hospitals across Japan over a 10-year period from 2006 to 2015.2 Loss of INI1,which is a negative regulator of EZH2, is observed in over 90% of epithelioid sarcoma cases,3 leading to [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":20287,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,89,211,237,182,206],"tags":[1715,7482,7481,424,7483],"ppma_author":[205],"class_list":["post-20248","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-health-tech","category-japan","category-news","category-pharma","category-regional","tag-eisai","tag-epithelioid-sarcoma","tag-ezh2","tag-pharma","tag-tazverik"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eisai\u2019s Tazemetostat Wins Orphan Drug Status in Japan<\/title>\n<meta name=\"description\" content=\"Eisai\u2019s Tazemetostat gains orphan drug designation in Japan for unresectable INI1-negative epithelioid sarcoma after chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/demo.itbusinesstoday.com\/ja\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai\u2019s Tazemetostat Wins Orphan Drug Status in Japan\" \/>\n<meta property=\"og:description\" content=\"Eisai\u2019s Tazemetostat gains orphan drug designation in Japan for unresectable INI1-negative epithelioid sarcoma after chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/demo.itbusinesstoday.com\/ja\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T10:22:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eisai\u2019s Tazemetostat Wins Orphan Drug Status in Japan","description":"Eisai\u2019s Tazemetostat gains orphan drug designation in Japan for unresectable INI1-negative epithelioid sarcoma after chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/demo.itbusinesstoday.com\/ja\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/","og_locale":"ja_JP","og_type":"article","og_title":"Eisai\u2019s Tazemetostat Wins Orphan Drug Status in Japan","og_description":"Eisai\u2019s Tazemetostat gains orphan drug designation in Japan for unresectable INI1-negative epithelioid sarcoma after chemotherapy.","og_url":"https:\/\/demo.itbusinesstoday.com\/ja\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/","og_site_name":"itbusinesstoday","article_published_time":"2025-09-01T10:22:15+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#article","isPartOf":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/"},"author":{"name":"NewsDesk","@id":"https:\/\/demo.itbusinesstoday.com\/#\/schema\/person\/485a13a98c34304fc32ae33d4dcff712"},"headline":"Eisai\u2019s Tazemetostat Approved as Orphan Drug in Japan","datePublished":"2025-09-01T10:22:15+00:00","mainEntityOfPage":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/"},"wordCount":264,"publisher":{"@id":"https:\/\/demo.itbusinesstoday.com\/#organization"},"image":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp","keywords":["Eisai","epithelioid sarcoma","EZH2","Pharma","Tazverik"],"articleSection":["APAC","Health Tech","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/","url":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/","name":"Eisai\u2019s Tazemetostat Wins Orphan Drug Status in Japan","isPartOf":{"@id":"https:\/\/demo.itbusinesstoday.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#primaryimage"},"image":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#primaryimage"},"thumbnailUrl":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp","datePublished":"2025-09-01T10:22:15+00:00","description":"Eisai\u2019s Tazemetostat gains orphan drug designation in Japan for unresectable INI1-negative epithelioid sarcoma after chemotherapy.","breadcrumb":{"@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#primaryimage","url":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp","contentUrl":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/09\/Ministry-Of-Health_-Labour-and-Welfare-Grants-Orphan-Drug-Designation-in-Japan-to.webp","width":1200,"height":800,"caption":"Eisai"},{"@type":"BreadcrumbList","@id":"https:\/\/demo.itbusinesstoday.com\/health-tech\/pharma\/eisais-tazemetostat-approved-as-orphan-drug-in-japan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/demo.itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Eisai\u2019s Tazemetostat Approved as Orphan Drug in Japan"}]},{"@type":"WebSite","@id":"https:\/\/demo.itbusinesstoday.com\/#website","url":"https:\/\/demo.itbusinesstoday.com\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/demo.itbusinesstoday.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/demo.itbusinesstoday.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/demo.itbusinesstoday.com\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/demo.itbusinesstoday.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/demo.itbusinesstoday.com\/#\/schema\/logo\/image\/","url":"https:\/\/itbt-staging-68b209.ingress-earth.ewp.live\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbt-staging-68b209.ingress-earth.ewp.live\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/demo.itbusinesstoday.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/demo.itbusinesstoday.com\/#\/schema\/person\/485a13a98c34304fc32ae33d4dcff712","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.pngf091576668ba5dc7a03619ffccba6942","url":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbt-staging-68b209.ingress-earth.ewp.live"],"url":"https:\/\/demo.itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/demo.itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=20248"}],"version-history":[{"count":1,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20248\/revisions"}],"predecessor-version":[{"id":20249,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/20248\/revisions\/20249"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/20287"}],"wp:attachment":[{"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=20248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=20248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=20248"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/demo.itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=20248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}